Get Started for FREE
Sign up with Facebook Sign up with Twitter
I don't have a Facebook or a Twitter account
 Your new post is loading...
Your new post is loading...
Scoop.it!
Preliminary results of Merck’s early-stage study evaluating its investigational lung cancer immunotherapy showed to trigger a response in roughly a quarter of participants. 
No comment yet.
Sign up to comment
Scoop.it!
Pertuzumab (Perjeta) in combination with trastuzumab and chemotherapy has become the first FDA-approved neoadjuvant treatment for patients with breast cancer.
Scoop.it!
CSL Behring announced that the US Food and Drug Administration (FDA) has approved a new dosing option for Hizentra in patients with primary immunodeficiency (PI).
Scoop.it!
Bristol-Myers Squibb Company recently announced results from a pooled analysis of survival data from 12 studies evaluating Yervoy (ipilimumab) in patients with metastatic or locally advanced or unresectable melanoma.
Scoop.it!
Health care reform will undoubtedly change the way specialty drugs are managed within the distribution supply chain, and specialty pharmacy providers may soon be competing with hospitals for patient share.
Scoop.it!
Prima BioMed Ltd recently announced top-line analysis of its mid-stage study evaluating its investigational ovarian cancer treatment.
Scoop.it!
Today, OncoMed Pharmaceuticals, Inc. announced that it has initiated a Phase Ib/II trial for its anti-cancer stem cell candidate for treatment of ovarian cancer.
Scoop.it!
Today, Sanofi announced that it temporarily withdrew the New Drug Application (NDA) for its experimental type 2 diabetes drug.
Scoop.it!
Viralytics Limited recently announced that its investigational melanoma trial achieved its primary endpoint for treatment of patients with late-stage melanoma.
Scoop.it!
The US Food and Drug Administration (FDA) issued a positive report ahead of the review of Genentech’s breast cancer drug Perjeta (pertuzumab).
Scoop.it!
Today, Novartis announced positive results from its late-stage study evaluating its psoriasis candidate versus Enbrel (etanercept).
Scoop.it!
Today, the US Food and Drug Administration (FDA) released a safety alert informing the public that a patient in Europe who was taking Gilenya (fingolimod) for treatment of multiple sclerosis (MS) developed a rare and serious brain infection.
|
Scoop.it!
According to a new study, a class of antidepressants has been identified as a potential new treatment for small cell lung cancer (SCLC).
Scoop.it!
Investigators in the Czech Republic have found an association between soft tissue lesions and diminished survival in patients with multiple myeloma.
Scoop.it!
Today, Eli Lilly and Company announced that its late-stage study of its breast cancer drug failed to meet its primary endpoint of progression-free survival (PFS).
Scoop.it!
Roche’s Genentech recently announced that Kadcyla (ado-trastuzumab emtansine) nearly doubled the time that people lived without their disease worsening compared to treatment of physician’s choice.
Scoop.it!
Between 21% and 28% of patients taking an oral therapy for hepatocellular carcinoma (HCC) were nonadherent to treatment. Certain groups of patients may benefit from counseling services that promote improved adherence.
Scoop.it!
Ablynx and AbbVie recently announced that they have entered into a global license agreement for the development and commercialization of a treatment for patients with rheumatoid arthritis.
Scoop.it!
A study compared historical and contemporary multiple sclerosis cases to determine how first-generation disease-modifying drugs affected disease progression.
Scoop.it!
Merck & Co Inc. has licensed its experimental mid-stage cancer drug to AstraZeneca for an upfront fee of $50 million.
Scoop.it!
Roche and Inovio Pharmaceuticals, Inc. announced that they have entered into an exclusive worldwide license agreement for immunotherapies for prostate cancer and hepatitis B.
Scoop.it!
Today, Oncolytics Biotech Inc. announced positive results from its mid-stage trial evaluating its lung cancer candidate.
|
